Cargando…
Clinical outcomes in estrogen receptor-positive early-stage breast cancer patients with Recurrence Score 26-30: observational real-world cohort study
Data on adjuvant chemotherapy (CT) benefit in ER + HER2‒ early-stage breast cancer (EBC) patients with Recurrence Score (RS) 26-30 are limited. This real-world study evaluated the relationships between the RS, adjuvant treatments, and outcomes in 534 RS 26-30 patients tested through Clalit Health Se...
Autores principales: | Rotem, Ofer, Peretz, Idit, Leviov, Michelle, Kuchuk, Iryna, Itay, Amit, Tokar, Margarita, Paluch-Shimon, Shani, Maimon, Ofra, Yerushalmi, Rinat, Drumea, Karen, Evron, Ella, Sonnenblick, Amir, Gal-Yam, Einav, Goldvaser, Hadar, Samih, Yosef, Merose, Rotem, Bareket-Samish, Avital, Soussan-Gutman, Lior, Stemmer, Salomon M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238504/ https://www.ncbi.nlm.nih.gov/pubmed/37268607 http://dx.doi.org/10.1038/s41523-023-00549-8 |
Ejemplares similares
-
Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry
por: Shachar, Shlomit S., et al.
Publicado: (2023) -
Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy
por: Stemmer, Salomon M., et al.
Publicado: (2019) -
Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry
por: Stemmer, Salomon M., et al.
Publicado: (2017) -
Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotective effects
por: Fishman, Pnina, et al.
Publicado: (2023) -
Namodenoson Inhibits the Growth of Pancreatic Carcinoma via Deregulation of the Wnt/β-catenin, NF-κB, and RAS Signaling Pathways
por: Itzhak, Inbal, et al.
Publicado: (2023)